Recombinant protein of human m
ethylmalonic aciduria (cobalamin deficiency) cblA type (MMAA), nuclear gene encoding mitochondrial protein- ￥2900
- OriGene
- TP323205
- 2026年03月19日
企业认证
相关产品推荐更多 >
Purified recombinant protein of Human deleted in azoospermia 4 (DAZ4), transcript variant 2, full length, with N-terminal HIS tag, expressed in E. coli, 50ug
￥2040Recombinant protein of human GULP, engulfment adaptor PTB domain containing 1 (GULP1)
￥2900Purified recombinant protein of Mouse GTP binding protein 6 (putative) (Gtpbp6), with C-terminal MYC/DDK tag, expressed in HEK293T cells, 20ug
￥2900Purified recombinant protein of Mouse EF-hand calcium binding domain 1 (Efcab1), with C-terminal MYC/DDK tag, expressed in HEK293T cells, 20ug
￥2900Recombinant protein of human chemokine (C-C motif) ligand 14 (CCL14), transcript variant 1
￥2900
万千商家帮你免费找货
0 人在求购买到急需产品
- 详细信息
- 文献和实验
- 技术资料
- 保存条件：
Store at -80°C.
- 保质期：
Stable for 12 months from the date of receipt of the product under proper storage and handling conditions. Avoid repeated freeze-thaw cycles.
- 英文名：
Recombinant protein of human methylmalonic aciduria (cobalamin deficiency) cblA type (MMAA), nuclear gene encoding mitochondrial protein
- 供应商：
OriGene
- 规格：
20 ug
风险提示：丁香通仅作为第三方平台，为商家信息发布提供平台空间。用户咨询产品时请注意保护个人信息及财产安全，合理判断，谨慎选购商品，商家和用户对交易行为负责。对于医疗器械类产品，请先查证核实企业经营资质和医疗器械产品注册证情况。
文献和实验Construction and Isolation of Recombinant MVA
Modified vaccinia virus Ankara (MVA) is a valuable tool for the expression of recombinant genes used for such purposes as the study of protein functions or characterization of cellular and humoral immune responses. A major advantage of MVA
Clinical Aspects of Ribozymes as Therapeutics in Gene Therapy
), as well as several other delivery systems (12 lipid mediated and 3 naked DNA delivery protocols). Treatment studies involving protein expression include replacement studies (e.g., ADA deficiency, cystic fibrosis, α-1-antitrypsin deficiency, Gaucher’s disease, familial
Ex Vivo Stromal Cell Electroporation of Factor IX cDNA for Treatment of Hemophilia B
of bleeding episodes and reduce long term complications (3). Treatment of hemophilia B primarily relies on intravenous injections of FIX protein purified from pooled human plasma, or very recently, on newly developed recombinant FIX. Treatment is applied
技术资料暂无技术资料 索取技术资料
